Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases
Authors:
Open Access
- 12 April 2024
- journal article
- review article
- Published by Taylor & Francis in Hematology
- Vol. 29 (1) , 2340144
Abstract
An association exists between immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis (HLH). Therefore, the main objective of this study was to collect data on this rare but potentially life-threatening immune-related adverse reaction to identify the medications that cause it, the clinical characteristics, and effective treatments. Literature in English and Chinese on immune checkpoint inhibitors causing HLH published from August 2014 to March 2024 was analyzed. Immune checkpoint inhibitors, immunotherapy, anti-PD-1, PD-L1 inhibitors, HLH, hemophagocytic lymphohistiocytosis, hemophagocytic syndrome keywords were used to find the literature on China Knowledge Network, Wanfang, PubMed and Emabase Databases. Twenty-four studies were included, with a total of 27 patients (18 males and 9 females) with a mean age of 58 years (range 26-86). The mean time to the onset of symptoms was 10.3 weeks (7 days-14 months). The main clinical characteristics were fever, cytopenia, splenomegaly, methemoglobinemia, hypofibrinogenemia, and bone marrow biopsy showed phagocytosis. Twenty-two patients improved after the treatment with steroids, cytokine blocking therapy and symptomatic treatment, four patients died, and one patient was not described. HLH should be not underestimated as a potentially serious adverse effect of immune checkpoint inhibitors since appropriate treatments may save the life of patients.Keywords
This publication has 54 references indexed in Scilit:
- Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapyCancer Reports, 2024
- Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysisInternational Journal of Cancer, 2022
- Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case reportClinical Case Reports, 2021
- Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosisAnnals of Oncology, 2020
- Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapyBest Practice & Research Clinical Rheumatology, 2020
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung CancerJAMA Oncology, 2019
- Diagnosis, Treatment, and Management of Hemophagocytic Lymphohistiocytosis in the Critical Care Unit2019
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceInvestigational New Drugs, 2017
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic SyndromeArthritis & Rheumatology, 2014
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006